Concept design of a superconducting magnet for a compact heavy-ion synchrotron

A compact synchrotron is now under development at the Nation-al Institutes for Quantum Science and Technology (QST), with the goal of downsizing the heavy-ion therapy system with super-conducting magnets conduction-cooled by GM cryocoolers. The synchrotron is required to accelerate several kinds of heavy-ion beams from 4 MeV/u to 430 MeV/u. A superconducting magnet with both dipole and quadrupole coils is adopted to generate a dipole field from 0.3 to 3.5 T and a quadrupole field from 0.1 to 1.5 T/m with a ramp rate of 0.6 T/s. A coil winding pattern and iron yoke are optimized to achieve field homogeneity in the re-quired area. For the small-scale synchrotron, the coil ends are op-timized with a novel parameter combining the beta function and multipole errors considering the beam dynamics

Electromagnetic design of the superconducting magnet for a compact heavy-ion synchrotron

A project to develop a compact heavy ion therapy device has been initiated at the National Institutes for Quantum and Radiological Science and Technology . The therapy device uses a 430 MeV/u synchrotron with superconducting bending magnets as a main accelerator. In order to reach the required output of the heavy ion beam, the bending magnets have been designed to be operate dalternately from 0.3 T (for to 3.5 T maximum (for extraction) at the ramping rate of 0.6 T/s. The 3D electromagnetic design of the synchrotron bending magnet has been performed. The magnetic length is 1.49 m for 45 degree bending angle, and curvature radius is 1.89 m. The superconducting coil consists of a low loss NbTi wire with a 1 mm diameter , and t he maximum operating current is 265A. To suppress the magnetomotive force, t he cross sectional coil designadopt ed an elliptical shaped arrangement. The coil and iron yoke designs were optimized for the uniformity of the magnetic field in the required area In addition, a short straight model with a magnetic length of 400 mm w as fabricated for the feasibility demonstration. The results of the excitation test as well as the electromagnetic design will be reported.27th International Conference on Magnet Technolog

A novel aqueous extract from rice fermented with Aspergillus oryzae and Saccharomyces cerevisiae possesses an anti-influenza A virus activity.

Human influenza virus infections occur annually worldwide and are associated with high morbidity and mortality. Hence, development of novel anti-influenza drugs is urgently required. Rice Power® extract developed by the Yushin Brewer Co. Ltd. is a novel aqueous extract of rice obtained via saccharization and fermentation with various microorganisms, such as Aspergillus oryzae, yeast [such as Saccharomyces cerevisiae], and lactic acid bacteria, possessing various biological and pharmacological properties. In our previous experimental screening with thirty types of Rice Power® extracts, we observed that the 30th Rice Power® (Y30) extract promoted the survival of influenza A virus-infected Madin-Darby canine kidney (MDCK) cells. Therefore, to identify compounds for the development of novel anti-influenza drugs, we aimed to investigate whether the Y30 extract exhibits anti-influenza A virus activity. In the present study, we demonstrated that the Y30 extract strongly promoted the survival of influenza A H1N1 Puerto Rico 8/34 (A/PR/8/34), California 7/09, or H3N2 Aichi 2/68 (A/Aichi/2/68) viruses-infected MDCK cells and inhibited A/PR/8/34 or A/Aichi/2/68 viruses infection and growth in the co-treatment and pre-infection experiments. The pre-treatment of Y30 extract on MDCK cells did not induce anti-influenza activity in the cell. The Y30 extract did not significantly affect influenza A virus hemagglutination, and neuraminidase and RNA-dependent RNA polymerase activities. Interestingly, the electron microscopy experiment revealed that the Y30 extract disrupts the integrity of influenza A virus particles by permeabilizing the viral membrane envelope, suggesting that Y30 extract has a direct virucidal effect against influenza A virus. Furthermore, we observed that compared to the ethyl acetate (EtOAc) extract, the water extract of Y30 extract considerably promoted the survival of cells infected with A/PR/8/34 virus. These results indicated that more anti-influenza components were present in the water extract of Y30 extract than in the EtOAc extract. Our results highlight the potential of a rice extract fermented with A. oryzae and S. cerevisiae as an anti-influenza medicine and a drug source for the development of anti-influenza compounds